TG Therapeutics
TGTX
331 hedge funds and large institutions have $2.92B invested in TG Therapeutics in 2024 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 98 increasing their positions, 98 reducing their positions, and 55 closing their positions.
51% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 55
23% more capital invested
Capital invested by funds: $2.38B → $2.92B (+$546M)
22% more call options, than puts
Call options by funds: $137M | Put options by funds: $113M
7% more funds holding
Funds holding: 308 → 331 (+23)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 98
3.25% less ownership
Funds ownership: 65.67% → 62.41% (-3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
+$52.7M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$47.5M |
| 3 |
BSA
Braun Stacey Associates
New York
|
+$12.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.2M |
| 5 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$60M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$42.1M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$40.3M |
| 4 |
Goldman Sachs
New York
|
-$28.2M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$22.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VFA
376
Values First Advisors
Gray,
Tennessee
| – | -$58.4K | -2,496 | Closed |
|
|
NFSG
377
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$39.8K | -1,700 | Closed |
|
378
Twin Tree Management
Dallas,
Texas
| – | -$32.3K | -1,380 | Closed |
|
|
GA
379
GoalVest Advisory
New York
| – | -$31.4K | -1,344 | Closed |
|
|
CA
380
Claris Advisors
St. Louis,
Missouri
| – | -$9.94K | -425 | Closed |
|
|
TWC
381
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$6.99K | -306 | Closed |
|
|
LOIM
382
Liberty One Investment Management
Libertyville,
Illinois
| – | -$3.6K | -154 | Closed |
|
|
CPA
383
Capital Performance Advisors
Walnut Creek,
California
| – | -$538 | -23 | Closed |
|
|
MFG
384
Mendota Financial Group
Madison,
Wisconsin
| – | -$94 | -4 | Closed |
|
|
HWM
385
Hemington Wealth Management
Falls Church,
Virginia
| – | +$57 | +2 | +33% |
|
TGTX Hedge Fund Activity: Q4 2024 in Review
331 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2024, worth a combined $2.92B — up 23% from $2.38B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new TGTX positions and 55 closed out — a net gain of 28 holders — while 98 added to existing stakes and 98 trimmed.
The largest buyer was ClearBridge Investments, opening a new position worth an estimated $52.7M. The largest seller was Woodline Partners, exiting entirely with an estimated $60M sold.
- 331 institutional investors held TG Therapeutics (TGTX) as of Q4 2024, up from 308 in Q3 2024.
- Funds reported $2.92B of TG Therapeutics stock for Q4 2024, up 23% quarter-over-quarter.
- 83 funds opened new TG Therapeutics positions in Q4 2024 and 55 closed out, a net change of +28 holders.
- The largest TG Therapeutics buyer in Q4 2024 was ClearBridge Investments, an estimated $52.7M added.
- The largest TG Therapeutics seller in Q4 2024 was Woodline Partners, an estimated $60M sold.
Based on aggregated 13F filings for Q4 2024.